Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness

Journal of Controlled Release

Volumn 239, Issue , 2016, Pages 10-18

  Fracasso, Giulio ^a   Falvo, Elisabetta ^b   Colotti, Gianni ^b   Fazi, Francesco ^c   Ingegnere, Tiziano ^d   Amalfitano, Adriana ^e   Doglietto, Giovanni Battista ^f   Alfieri, Sergio ^f   Boffi, Alberto ^b,c   Morea, Veronica ^b   Conti, Giamaica ^g   Tremante, Elisa ^d   Giacomini, Patrizio ^d   Arcovito, Alessandro ^e   Ceci, Pierpaolo ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b CNR   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g UNIVERSITY OF VERONA   (Italy)

Author keywords

Drug delivery; Ferritin; Nuclear localization; Pancreatic cancer; PASylation; Protein cage nanocarrier

Indexed keywords

AMINO ACIDS; CELLS; DIAGNOSIS; DRUG DELIVERY; ENZYME INHIBITION; PEPTIDES; TUMORS;

FERRITIN; NANOCARRIERS; NUCLEAR LOCALIZATION; PANCREATIC CANCERS; PASYLATION;

DISEASES;

ALANINE; ALDOXORUBICIN; CD71 ANTIGEN; DOXORUBICIN; FERRITIN; FERRITIN HEAVY CHAIN; GELATINASE A; GELATINASE B; NANOCARRIER; POLYPEPTIDE; PROLINE; SERINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; APOFERRITIN; DRUG CARRIER; NANOPARTICLE;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL NUCLEUS; CELL PROLIFERATION ASSAY; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; FIBROSARCOMA CELL LINE; FLOW CYTOMETRY; GENE CONSTRUCT; HUMAN; HUMAN CELL; IN VITRO STUDY; LYSOSOME; MEDIAN SURVIVAL TIME; METASTASIS; MOUSE; MULTIPLE CYCLE TREATMENT; NANOENCAPSULATION; NONHUMAN; PANCREAS ADENOCARCINOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; SURFACE PLASMON RESONANCE; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; NUDE MOUSE; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOFERRITINS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICE; MICE, NUDE; NANOPARTICLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84982144525     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.08.010     Document Type: Article

References (35)

1. [1] Falvo, E., Tremante, E., Fraioli, R., Leonetti, C., Zamparelli, C., Boffi, A., Morea, V., Ceci, P., Giacomini, P., Antibody-drug conjugates: targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin. Nanoscale 5 (2013), 12278–12285.
2. [2] Zhen, Z., Tang, W., Chen, H., Lin, X., Todd, T., Wang, G., Cowger, T., Chen, X., Xie, J., RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors. ACS Nano 7 (2013), 4830–4837.
3. [3] Fan, K., Cao, C., Pan, Y., Lu, D., Yang, D., Feng, J., Song, L., Liang, M., Yan, X., Magnetoferritin nanoparticles for targeting and visualizing tumour tissues. Nat. Nanotechnol. 7 (2012), 459–464.
4. [4] Vannucci, L., Falvo, E., Fornara, M., Di Micco, P., Benada, O., Krizan, J., Svoboda, J., Hulikova-Capkova, K., Morea, V., Boffi, A., Ceci, P., Selective targeting of melanoma by PEG-masked protein-based multifunctional nanoparticles. Int. J. Nanomedicine 7 (2012), 1489–1509.
5. [5] Vannucci, L., Falvo, E., Failla, C.M., Carbo, M., Fornara, M., Canese, R., Cecchetti, S., Rajsiglova, L., Stakheev, D., Krizan, J., Boffi, A., Carpinelli, G., Morea, V., Ceci, P., In vivo targeting of cutaneous melanoma using an melanoma stimulating hormone-engineered human protein cage with fluorophore and magnetic resonance imaging tracers. J. Biomed. Nanotechnol. 11 (2015), 81–92.
6. [6] Liang, M., Fan, K., Zhou, M., Duan, D., Zheng, J., Yang, D., Feng, J., Yan, X., H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 14900–14905.
7. [7] Bellini, M., Mazzucchelli, S., Galbiati, E., Sommaruga, S., Fiandra, L., Truffi, M., Rizzuto, M.A., Colombo, M., Tortora, P., Corsi, F., Prosperi, D., Protein nanocages for self-triggered nuclear delivery of DNA-targeted chemotherapeutics in cancer cells. J. Control. Release 196 (2014), 184–196.
8. [8] Heger, Z., Skalickova, S., Zitka, O., Adam, V., Kizek, R., Apoferritin applications in nanomedicine. Nanomedicine-UK 9 (2014), 2233–2245.
9. [9] Bellapadrona, G., Sinkar, S., Sabanay, H., Liljestrom, V., Kostiainen, M., Elbaum, M., Supramolecular assembly and coalescence of ferritin cages driven by designed protein–protein interactions. Biomacromolecules 16 (2015), 2006–2011.
10. [10] Kang, Y.J., Park, D.C., Shin, H.H., Park, J., Kang, S., Incorporation of thrombin cleavage peptide into a protein cage for constructing a protease-responsive multifunctional delivery nanoplatform. Biomacromolecules 13 (2012), 4057–4064.
11. [11] Schoonen, L., van Hest, J.C., Functionalization of protein-based nanocages for drug delivery applications. Nanoscale 6 (2014), 7124–7141.
12. [12] Truffi, M., Fiandra, L., Sorrentino, L., Monieri, M., Corsi, F., Mazzucchelli, S., Ferritin nanocages: a biological platform for drug delivery, imaging and theranostics in cancer. Pharmacol. Res. 107 (2016), 57–65.
13. [13] Lee, J.H., Seo, H.S., Song, J.A., Kwon, K.C., Lee, E.J., Kim, H.J., Lee, E.B., Cha, Y.J., Lee, J., Proteinticle engineering for accurate 3D diagnosis. ACS Nano 7 (2013), 10879–10886.
14. [14] Lee, E.J., Lee, N.K., Kim, I.S., Bioengineered protein-based nanocage for drug delivery. Adv. Drug Deliv. Rev., 2016.
15. [15] Li, L., Zhang, L., Knez, M., Comparison of two endogenous delivery agents in cancer therapy: exosomes and ferritin. Pharmacol. Res., 2016.
16. [16] Uchida, M., Willits, D.A., Muller, K., Willis, A.F., Jackiw, L., Jutila, M., Young, M.J., Porter, A.E., Douglas, T., Intracellular distribution of macrophage targeting ferritin-iron oxide nanocomposite. Adv. Mater. 21 (2009), 458–462.
17. [17] Crich, S.G., Bussolati, B., Tei, L., Grange, C., Esposito, G., Lanzardo, S., Camussi, G., Aime, S., Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. Cancer Res. 66 (2006), 9196–9201.
18. [18] Lin, X., Xie, J., Niu, G., Zhang, F., Gao, H., Yang, M., Quan, Q., Aronova, M.A., Zhang, G., Lee, S., Leapman, R., Chen, X., Chimeric ferritin nanocages for multiple function loading and multimodal imaging. Nano Lett. 11 (2011), 814–819.
19. [19] Fantechi, E., Innocenti, C., Zanardelli, M., Fittipaldi, M., Falvo, E., Carbo, M., Shullani, V., Di Cesare Mannelli, L., Ghelardini, C., Ferretti, A.M., Ponti, A., Sangregorio, C., Ceci, P., A smart platform for hyperthermia application in cancer treatment: cobalt-doped ferrite nanoparticles mineralized in human ferritin cages. ACS Nano 8 (2014), 4705–4719.
20. [20] Liu, X.Y., Wei, W., Huang, S.J., Lin, S.S., Zhang, X., Zhang, C.M., Du, Y.G., Ma, G.H., Li, M., Mann, S., Ma, D., Bio-inspired protein-gold nanoconstruct with core-void-shell structure: beyond a chemo drug carrier. J. Mater. Chem. B 1 (2013), 3136–3143.
21. [21] Bode, S.A., Minten, I.J., Nolte, R.J., Cornelissen, J.J., Reactions inside nanoscale protein cages. Nanoscale 3 (2011), 2376–2389.
22. [22] Li, L., Fang, C.J., Ryan, J.C., Niemi, E.C., Lebron, J.A., Bjorkman, P.J., Arase, H., Torti, F.M., Torti, S.V., Nakamura, M.C., Seaman, W.E., Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 3505–3510.
23. [23] Falvo, E., Tremante, E., Arcovito, A., Papi, M., Elad, N., Boffi, A., Morea, V., Conti, G., Toffoli, G., Fracasso, G., Giacomini, P., Ceci, P., Improved doxorubicin encapsulation and pharmacokinetics of ferritin-fusion protein nanocarriers bearing proline, serine, and alanine elements. Biomacromolecules, 2015.
24. [24] Schlapschy, M., Binder, U., Borger, C., Theobald, I., Wachinger, K., Kisling, S., Haller, D., Skerra, A., PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins. Protein Eng. Des. Sel. 26 (2013), 489–501.
25. [25] Rundhaug, J.E., Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00. Clin. Cancer Res. 9:2003 (2003), 551–554.
26. [26] Fan, K., Gao, L., Yan, X., Human ferritin for tumor detection and therapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5 (2013), 287–298.
27. [27] Shi, N.Q., Gao, W., Xiang, B., Qi, X.R., Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage. Int. J. Nanomedicine 7 (2012), 1613–1621.
28. [28] Zhang, L.B., Li, L., Di Penta, A., Carmona, U., Yang, F., Schops, R., Brandsch, M., Zugaza, J.L., Knez, M., H-chain ferritin: a natural nuclei targeting and bioactive delivery nanovector. Adv. Healthc. Mater. 4 (2015), 1305–1310.
29. [29] Beyer, U., Rothen-Rutishauser, B., Unger, C., Wunderli-Allenspach, H., Kratz, F., Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy. (vol 18, pg 29, 2001). Pharm. Res.-Dordr., 18, 2001, 719.
30. [30] Monti, P., Marchesi, F., Reni, M., Mercalli, A., Sordi, V., Zerbi, A., Balzano, G., Di Carlo, V., Allavena, P., Piemonti, L., A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Arch. 445 (2004), 236–247.
31. [31] Kratz, F., Azab, S., Zeisig, R., Fichtner, I., Warnecke, A., Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model. Int. J. Pharm. 441 (2013), 499–506.
32. [32] Kratz, F., Fichtner, I., Graeser, R., Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model. Investig. New Drugs 30 (2012), 1743–1749.
33. [33] Unger, C., Haring, B., Medinger, M., Drevs, J., Steinbild, S., Kratz, F., Mross, K., Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin. Cancer Res. 13 (2007), 4858–4866.
34. [34] Norton, L., Simon, R., Brereton, H.D., Bogden, A.E., Predicting the course of Gompertzian growth. Nature 264 (1976), 542–545.
35. [35] Bernabeu, E., Helguera, G., Legaspi, M.J., Gonzalez, L., Hocht, C., Taira, C., Chiappetta, D.A., Paclitaxel-loaded PCL-TPGS nanoparticles: in vitro and in vivo performance compared with Abraxane(R). Colloids Surf. B: Biointerfaces 113 (2014), 43–50.